Table 4.
Meta-analysis of percentage of variance explained in depression phenotype in NHS by the genetic risk scores using external GAIN-MDD sample as the training set (N = 6989).
| Outcome in NHS testing set | ||||
|---|---|---|---|---|
| Continuous depression score |
Dichotomous depression status |
|||
| Ptraining threshold | R2%1 | P-value1 | R2%1, 2 | P-value1 |
| p<0.00001 | — | — | — | — |
| p<0.0001 | 0.1 | 0.807 | 0.1 | 0.697 |
| p<0.001 | 0.1 | 0.203 | 0.2 | 0.450 |
| p<0.01 | 0 | 0.866 | 0 | 0.775 |
| p<0.1 | 0 | 0.922 | 0.1 | 0.520 |
| p<0.2 | 0 | 0.581 | 0 | 0.863 |
| p<0.3 | 0 | 0.394 | 0.1 | 0.903 |
| p<0.4 | 0 | 0.300 | 0.1 | 0.651 |
| p<0.5 | 0.1 | 0.344 | 0.1 | 0.653 |
GWAS, genome-wide association studies; GAIN-MDD, Genetic Association Information Network—Major Depressive Disorder; NHS, Nurses' Health Study.
1
Use the GWAS result from GAIN-MDD as the training set, and use each of the four NHS substudies as the testing set on recurrent composite depression score. The final weighted R2 and P-value calculated meta-analytically across four NHS substudies.
2
Denotes Nagelkerke's R2%.